Hypoxia-active nanoparticles used in tumor theranostic

References

• Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008;8(1):56–61. doi:10.1038/nrc225518059462
   PubMed Web of Science ®Google Scholar
• Lewis DM, Park KM, Tang V, et al. Intratumoral oxygen gradients mediate sarcoma cell invasion. Proc Natl Acad Sci U S A. 2016;113(33):9292–9297. doi:10.1073/pnas.160531711327486245
   PubMedGoogle Scholar
• Da Motta LL, Ledaki I, Purshouse K, et al. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene. 2017;36(1):122–132. doi:10.1038/onc.2016.18427292261
   PubMedGoogle Scholar
• Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater. 2013;12(11):958–962. doi:10.1038/nmat379224150413
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393–410. doi:10.1038/nrc306421606941
   PubMed Web of Science ®Google Scholar
• Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8(12):967–975.18987634
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.21258394
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–239.17440684
   PubMed Web of Science ®Google Scholar
• Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430–439. doi:10.1038/nrc372624827502
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47. doi:10.1038/nrc70411902584
   PubMed Web of Science ®Google Scholar
• Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12(1):9–22. doi:10.1038/nrc318322169972
   PubMed Web of Science ®Google Scholar
• Loscalzo J. Adaptions to hypoxia and redox stress: essential concepts confounded by misleading terminology. Circ Res. 2016;119(4):511–513. doi:10.1161/CIRCRESAHA.116.30939427492841
   PubMedGoogle Scholar
• Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem. 2001;8(7):739–761.11375747
   PubMed Web of Science ®Google Scholar
• Schwartz HS, Sodergren JE, Philips FS. MITOMYCIN C: CHEMICAL AND BIOLOGICAL STUDIES ON ALKYLATION. Science (New York, NY). 1963;142(3596):1181–1183. doi:10.1126/science.142.3596.1181
   Google Scholar
• Iyer VN, Szybalski W. MITOMYCINS AND PORFIROMYCIN: CHEMICAL MECHANISM OF ACTIVATION AND CROSS-LINKING OF DNA. Science (New York, NY). 1964;145(3627):55–58. doi:10.1126/science.145.3627.55
   Google Scholar
• Kumar R, Kim EJ, Han J, et al. Hypoxia-directed and activated theranostic agent: imaging and treatment of solid tumor. Biomaterials. 2016;104:119–128. doi:10.1016/j.biomaterials.2016.07.01027449948
   PubMed Web of Science ®Google Scholar
• de Groot FM, Damen EW, Scheeren HW. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem. 2001;8(9):1093–1122.11472243
   PubMed Web of Science ®Google Scholar
• Qiao Y, Wan J, Zhou L, et al. Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018; 11(1). doi:10.1002/wnan.1527.
   PubMed Web of Science ®Google Scholar
• Sharma A, Arambula JF, Koo S, et al. Hypoxia-targeted drug delivery. Chem Soc Rev. 2019;48(3):771–813. doi:10.1039/c8cs00304a30575832
   PubMed Web of Science ®Google Scholar
• Piao W, Hanaoka K, Fujisawa T, et al. Development of an azo-based photosensitizer activated under mild hypoxia for photodynamic therapy. J Am Chem Soc. 2017;139(39):13713–13719. doi:10.1021/jacs.7b0501928872304
   PubMedGoogle Scholar
• Yamamoto N, Renfrew AK, Kim BJ, Bryce NS, Hambley TW. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex. J Med Chem. 2012;55(24):11013–11021. doi:10.1021/jm301471323199008
   PubMed Web of Science ®Google Scholar
• Xie Z, Ma L, deKrafft KE, Jin A, Lin W. Porous phosphorescent coordination polymers for oxygen sensing. J Am Chem Soc. 2010;132(3):922–923. doi:10.1021/ja909629f20041656
   PubMedGoogle Scholar
• Finikova OS, Cheprakov AV, Vinogradov SA. Synthesis and luminescence of soluble meso-unsubstituted tetrabenzo- and tetranaphtho[2,3]porphyrins. J Org Chem. 2005;70(23):9562–9572. doi:10.1021/jo051580r16268634
   PubMedGoogle Scholar
• Neugebauer U, Pellegrin Y, Devocelle M, et al.Ruthenium polypyridyl peptide conjugates: membrane permeable probes for cellular imaging. Chem Commun (Camb). 2008;(42):5307–5309. doi:10.1039/b810403d18985192
   PubMedGoogle Scholar
• Zhang S, Hosaka M, Yoshihara T, et al. Phosphorescent light-emitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals. Cancer Res. 2010;70(11):4490–4498. doi:10.1158/0008-5472.CAN-09-394820460508
   PubMedGoogle Scholar
• Tobita S, Yoshihara T. Intracellular and in vivo oxygen sensing using phosphorescent iridium(III) complexes. Curr Opin Chem Biol. 2016;33:39–45. doi:10.1016/j.cbpa.2016.05.01727281510
   PubMedGoogle Scholar
• Lv W, Yang T, Yu Q, et al. A phosphorescent iridium(III) complex-modified nanoprobe for hypoxia bioimaging via time-resolved luminescence microscopy. Adv Sci (Weinh). 2015;2(10):1500107. doi:10.1002/advs.20150008827980906
   PubMedGoogle Scholar
• Lv W, Zhang Z, Zhang KY, et al. A mitochondria-targeted photosensitizer showing improved photodynamic therapy effects under hypoxia. Angew Chem Int Ed Engl. 2016;55(34):9947–9951. doi:10.1002/anie.20160413027381490
   PubMed Web of Science ®Google Scholar
• Feng Z, Tao P, Zou L, et al. Hyperbranched phosphorescent conjugated polymer dots with iridium(III) complex as the core for hypoxia imaging and photodynamic therapy. ACS Appl Mater Interfaces. 2017;9(34):28319–28330. doi:10.1021/acsami.7b0972128795796
   PubMedGoogle Scholar
• Zhu C, Liu L, Yang Q, Lv F, Wang S. Water-soluble conjugated polymers for imaging, diagnosis, and therapy. Chem Rev. 2012;112(8):4687–4735. doi:10.1021/cr200263w22670807
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Bu W, et al. Ultrasensitive nanosensors based on upconversion nanoparticles for selective hypoxia imaging in vivo upon near-infrared excitation. J Am Chem Soc. 2014;136(27):9701–9709. doi:10.1021/ja504298924956326
   PubMedGoogle Scholar
• Papkovsky DB, Dmitriev RI. Biological detection by optical oxygen sensing. Chem Soc Rev. 2013;42(22):8700–8732. doi:10.1039/c3cs60131e23775387
   PubMedGoogle Scholar
• Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol. 2001;19(4):316–317. doi:10.1038/8668411283581
   PubMed Web of Science ®Google Scholar
• Lv Z, Zou L, Wei H, Liu S, Huang W, Zhao Q. Phosphorescent starburst Pt(II) porphyrins as bifunctional therapeutic agents for tumor hypoxia imaging and photodynamic therapy. ACS Appl Mater Interfaces. 2018;10(23):19523–19533. doi:10.1021/acsami.8b0594429771486
   PubMedGoogle Scholar
• Zhao Q, Zhou X, Cao T, et al. Fluorescent/phosphorescent dual-emissive conjugated polymer dots for hypoxia bioimaging. Chem Sci. 2015;6(3):1825–1831. doi:10.1039/c4sc03062a28694947
   PubMedGoogle Scholar
• Zhou X, Liang H, Jiang P, et al. Multifunctional phosphorescent conjugated polymer dots for hypoxia imaging and photodynamic therapy of cancer cells. Adv Sci (Weinh). 2016;3(2):1500155.27722081
   PubMedGoogle Scholar
• Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38(7):1155–1160.9225812
   PubMed Web of Science ®Google Scholar
• Lopci E, Grassi I, Rubello D, et al. Prognostic evaluation of disease outcome in solid tumors investigated with 64Cu-ATSM PET/CT. Clin Nucl Med. 2016;41(2):e87–e92. doi:10.1097/RLU.000000000000101726447388
   PubMedGoogle Scholar
• Yu J, Zhang Y, Hu X, Wright G, Gu Z. Hypoxia-sensitive materials for biomedical applications. Ann Biomed Eng. 2016;44(6):1931–1945. doi:10.1007/s10439-016-1578-626926694
   PubMedGoogle Scholar
• Liu K, Zhu HL. Nitroimidazoles as anti-tumor agents. Anticancer Agents Med Chem. 2011;11(7):687–691. doi:10.2174/18715201179681766421521156
   PubMed Web of Science ®Google Scholar
• Zbaida S, Levine WG. A novel application of cyclic voltammetry for direct investigation of metabolic intermediates in microsomal azo reduction. Chem Res Toxicol. 1991;4(1):82–88.1912304
   PubMed Web of Science ®Google Scholar
• Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22(3):265–280.7789400
   PubMedGoogle Scholar
• Liu H, Xie Y, Zhang Y, et al. Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. Biomaterials. 2017;121:130–143. doi:10.1016/j.biomaterials.2017.01.00128088075
   PubMed Web of Science ®Google Scholar
• Spencer JA, Ferraro F, Roussakis E, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 2014;508(7495):269–273. doi:10.1038/nature1303424590072
   PubMed Web of Science ®Google Scholar
• Lin QN, Bao CY, Yang YL, et al. Highly discriminating photorelease of anticancer drugs based on hypoxia activatable phototrigger conjugated chitosan nanoparticles. Adv Mater. 2013;25(14):1981–1986. doi:10.1002/adma.20120445523401259
   PubMed Web of Science ®Google Scholar
• Liu F, Lou JZ, Hristov D. X-Ray responsive nanoparticles with triggered release of nitrite, a precursor of reactive nitrogen species, for enhanced cancer radiosensitization. Nanoscale. 2017;9(38):14627–14634. doi:10.1039/c7nr04684g28936509
   PubMedGoogle Scholar
• Dobrowsky W, Huigol NG, Jayatilake RS, et al. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial. Radiother Oncol. 2007;82(1):24–29. doi:10.1016/j.radonc.2006.11.00717161478
   PubMed Web of Science ®Google Scholar
• Pasupathy K, Nair CK, Kagiya TV. Effect of a hypoxic radiosensitizer, AK 2123 (Sanazole), on yeast Saccharomyces cerevisiae. J Radiat Res. 2001;42(2):217–227.11599887
   PubMed Web of Science ®Google Scholar
• Sreeja S, Krishnan Nair CK. Tumor control by hypoxia-specific chemotargeting of iron-oxide nanoparticle - Berberine complexes in a mouse model. Life Sci. 2018;195:71–80. doi:10.1016/j.lfs.2017.12.03629289560
   PubMedGoogle Scholar
• Sreeja S, Nair CKK. Chemo-directed specific targeting of nanoparticle-doxorubicin complexes to tumor in animal model. J Drug Deliv Sci Technol. 2016;31:167–175. doi:10.1016/j.jddst.2016.01.003
   Web of Science ®Google Scholar
• Erdogar N, Iskit AB, Eroglu H, Sargon MF, Mungan NA, Bilensoy E. Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy. Int J Pharm. 2014;471(1–2):1–9. doi:10.1016/j.ijpharm.2014.05.01424836669
   PubMedGoogle Scholar
• Carames Masana F, de Reijke TM. The efficacy of Apaziquone in the treatment of bladder cancer. Expert Opin Pharmacother. 2017;18(16):1781–1788. doi:10.1080/14656566.2017.139251029034722
   PubMed Web of Science ®Google Scholar
• Pierce SE, Guziec LJ, Guziec FS, Brodbelt JS. Characterization of aziridinylbenzoquinone DNA cross-links by liquid chromatography-infrared multiphoton dissociation-mass spectrometry. Chem Res Toxicol. 2010;23(6):1097–1104. doi:10.1021/tx100073820369834
   PubMedGoogle Scholar
• Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH: cytochromeC (P-450) reductase and DT-diaphorase. Adv Enzyme Regul. 1998;38:111–133.9762350
   PubMedGoogle Scholar
• Rauth AM, Mohindra JK, Tannock IF. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res. 1983;43(9):4154–4158.6409398
   PubMed Web of Science ®Google Scholar
• Hou ZQ, Wei H, Wang Q, et al. New method to prepare mitomycin C Loaded PLA-nanoparticles with high drug entrapment efficiency. Nanoscale Res Lett. 2009;4(7):732–737. doi:10.1007/s11671-009-9312-z20596446
   PubMedGoogle Scholar
• Hou Z, Li Y, Huang Y, et al. Phytosomes loaded with mitomycin C-soybean phosphatidylcholine complex developed for drug delivery. Mol Pharm. 2013;10(1):90–101. doi:10.1021/mp300489p23194396
   PubMed Web of Science ®Google Scholar
• Zhang P, Huang H, Chen Y, Wang J, Ji L, Chao H. Ruthenium(II) anthraquinone complexes as two-photon luminescent probes for cycling hypoxia imaging in vivo. Biomaterials. 2015;53:522–531. doi:10.1016/j.biomaterials.2015.02.12625890748
   PubMedGoogle Scholar
• Qian C, Yu J, Chen Y, et al. Light-activated hypoxia-responsive nanocarriers for enhanced anticancer therapy. Adv Mater. 2016;28(17):3313–3320. doi:10.1002/adma.20150586926948067
   PubMed Web of Science ®Google Scholar
• McCarthy HO, Yakkundi A, McErlane V, et al. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 2003;10(1):40–48. doi:10.1038/sj.cgt.770052212489027
   PubMed Web of Science ®Google Scholar
• Nishida CR, Lee M, de Montellano PR. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol. 2010;78(3):497–502. doi:10.1124/mol.110.06504520566689
   PubMed Web of Science ®Google Scholar
• Nishida CR, Ortiz de Montellano PR. Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase. J Med Chem. 2008;51(16):5118–5120. doi:10.1021/jm800496s18681417
   PubMedGoogle Scholar
• Mehibel M, Singh S, Chinje EC, Cowen RL, Stratford IJ. Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N). Mol Cancer Ther. 2009;8(5):1261–1269. doi:10.1158/1535-7163.MCT-08-092719435866
   PubMed Web of Science ®Google Scholar
• Paoni NF, Peale F, Wang F, et al. Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice. Physiol Genomics. 2002;11(3):263–272. doi:10.1152/physiolgenomics.00110.200212399448
   PubMedGoogle Scholar
• Knox HJ, Hedhli J, Kim TW, Khalili K, Dobrucki LW, Chan J. A bioreducible N-oxide-based probe for photoacoustic imaging of hypoxia. Nat Commun. 2017;8(1):1794. doi:10.1038/s41467-017-01951-029176550
   PubMedGoogle Scholar
• Feng L, Cheng L, Dong Z, et al. Theranostic liposomes with hypoxia-activated prodrug to effectively destruct hypoxic tumors post-photodynamic therapy. ACS Nano. 2017;11(1):927–937.28027442
   PubMed Web of Science ®Google Scholar
• Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 2002;62(18):5248–5253.12234992
   PubMed Web of Science ®Google Scholar
• Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys. 1986;12(7):1239–1242.3744945
   PubMed Web of Science ®Google Scholar
• Shinde SS, Hay MP, Patterson AV, Denny WA, Anderson RF. Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J Am Chem Soc. 2009;131(40):14220–14221.19772319
   PubMed Web of Science ®Google Scholar
• Delahoussaye YM, Evans JW, Brown JM. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol. 2001;62(9):1201–1209.11705453
   PubMed Web of Science ®Google Scholar
• Patterson AV, Saunders MP, Chinje EC, Patterson LH, Stratford IJ. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des. 1998;13(6):541–573.9755718
   PubMedGoogle Scholar
• Wang Y, Xie Y, Li J, et al. Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy. ACS Nano. 2017;11(2):2227–2238.28165223
   PubMed Web of Science ®Google Scholar
• Guo D, Xu S, Wang N, et al. Prodrug-embedded angiogenic vessel-targeting nanoparticle: A positive feedback amplifier in hypoxia-induced chemo-photo therapy. Biomaterials. 2017;144:188–198.28837960
   PubMed Web of Science ®Google Scholar
• Liu M, Wang L, Zheng X, Liu S, Xie Z. Hypoxia-triggered nanoscale metal-organic frameworks for enhanced anticancer activity. ACS Appl Mater Interfaces. 2018;10(29):24638–24647.29957930
   PubMed Web of Science ®Google Scholar
• Zhao P, Ren S, Liu Y, Huang W, Zhang C, He J. PL-W18O49-TPZ nanoparticles for simultaneous hypoxia-activated chemotherapy and photothermal therapy. ACS Appl Mater Interfaces. 2018;10(4):3405–3413.29313656
   PubMed Web of Science ®Google Scholar
• Feng Q, Li Y, Yang X, et al. Hypoxia-specific therapeutic agents delivery nanotheranostics: a sequential strategy for ultrasound mediated on-demand tritherapies and imaging of cancer. J Control Release. 2018;275:192–200.29474964
   PubMed Web of Science ®Google Scholar
• Lee J, Oh ET, Yoon H, et al. Mesoporous nanocarriers with a stimulus-responsive cyclodextrin gatekeeper for targeting tumor hypoxia. Nanoscale. 2017;9(20):6901–6909.28503686
   PubMed Web of Science ®Google Scholar
• Wang W, Lin L, Ma X, et al. Light-induced hypoxia-triggered living nanocarriers for synergistic cancer therapy. ACS Appl Mater Interfaces. 2018;10(23):19398–19407.29781276
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu M, Li J, et al. Light-enhanced hypoxia-response of conjugated polymer nanocarrier for successive synergistic photodynamic and chemo-therapy. ACS Appl Mater Interfaces. 2018;10(26):21909–21919.29882654
   PubMed Web of Science ®Google Scholar
• Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8(3):173–184.17304245
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067–U1140.20305636
   PubMed Web of Science ®Google Scholar
• Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 1999;6(4):595–605.10476219
   PubMed Web of Science ®Google Scholar
• Takae S, Miyata K, Oba M, et al. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J Am Chem Soc. 2008;130(18):6001–6009.18396871
   PubMed Web of Science ®Google Scholar
• Perche F, Biswas S, Wang T, Zhu L, Torchilin VP. Hypoxia-targeted siRNA delivery. Angew Chem Int Ed Engl. 2014;53(13):3362–3366.24554550
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng. 2011;2:281–298.22432620
   PubMed Web of Science ®Google Scholar
• Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng. 2012;40(1):21–41.22428797
   PubMedGoogle Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73(8):2412–2417.23423979
   PubMed Web of Science ®Google Scholar
• Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9(5):1909–1915.19344179
   PubMed Web of Science ®Google Scholar
• Xie Z, Guo W, Guo N, et al. Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy. Acta Biomater. 2018;71:351–362.29545193
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–732.13130303
   PubMed Web of Science ®Google Scholar
• Lu ZG, Li Y, Shi YJ, Li YH, Xiao ZB, Zhang X. Traceable nanoparticles with spatiotemporally controlled release ability for synergistic glioblastoma multiforme treatment. Adv Funct Mater. 2017;27(46):13.
   Web of Science ®Google Scholar
• Yang HY, Li Y, Lee DS. Multifunctional and stimuli-responsive magnetic nanoparticle-based delivery systems for biomedical applications. Adv Ther. 2018;1(2):1800011.
   Google Scholar
• Guo D, Xu S, Huang Y, et al. Platinum(IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy. Biomaterials. 2018;177:67–77.29885587
   PubMed Web of Science ®Google Scholar
• Denny WA, Wilson WR. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev. 1993;12(2):135–151.8375017
   PubMed Web of Science ®Google Scholar
• de Souza IC, Faro LV, Pinheiro CB, et al. Investigation of cobalt(iii)-triazole systems as prototypes for hypoxia-activated drug delivery. Dalton Trans. 2016;45(35):13671–13674.27488398
   PubMed Web of Science ®Google Scholar
• Renfrew AK, Bryce NS, Hambley TW. Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study. Chem Sci. 2013;4(9):3731–3739.
   Web of Science ®Google Scholar
• Sowa T, Menju T, Chen-Yoshikawa TF, et al. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Cancer Med. 2017;6(1):288–297.28028936
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol. 2015;31:52–64. doi:10.1016/j.semcancer.2014.08.00225117006
   PubMed Web of Science ®Google Scholar
• Dubois L, Douma K, Supuran CT, et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol. 2007;83(3):367–373. doi:10.1016/j.radonc.2007.04.01817502120
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani RM, et al. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials. 2018;183:280–294. doi:10.1016/j.biomaterials.2018.08.05330179778
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu LQ. Design of Anticancer Prodrugs for Reductive Activation. Med Res Rev. 2009;29(1):29–64. doi:10.1002/med.2013718688784
   PubMed Web of Science ®Google Scholar
• Phillips RM, Hendriks HR, Peters GJ. EO9 (Apaziquone): from the clinic to the laboratory and back again. Br J Pharmacol. 2013;168(1):11–18. doi:10.1111/j.1476-5381.2012.01996.x22509926
   PubMedGoogle Scholar
• Komatsu H, Tanabe K, Nishimoto S. C-13-labeled indolequinone-DTPA-Gd conjugate for NMR probing cytochrome: P450 reductase-mediated one-electron reduction. Bioorg Med Chem Lett. 2011;21(2):790–793. doi:10.1016/j.bmcl.2010.11.10521168332
   PubMedGoogle Scholar
• Nemeikaite-Ceniene A, Sarlauskas J, Anusevicius Z, Nivinskas H, Cenas N. Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H: quinoneoxidoreductase (NQO1) and oxidative stress. Arch Biochem Biophys. 2003;416(1):110–118.12859987
   PubMed Web of Science ®Google Scholar
• Yang YP, Kuo HS, Tsai HD, Peng YC, Lin YL. The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone. Breast Cancer Res. 2005;7(1):R19–R27. doi:10.1186/bcr93915642166
   PubMedGoogle Scholar
• Li Y, Sun Y, Li J, et al. Ultrasensitive near-infrared fluorescence-enhanced probe for in vivo nitroreductase imaging. J Am Chem Soc. 2015;137(19):6407–6416. doi:10.1021/jacs.5b0409725923361
   PubMedGoogle Scholar
• Maurin MB, Rowe SM, Field KS, Swintosky RC, Hussain MA. Solubility behavior, phase transition, and structure-based nucleation inhibition of etanidazole in aqueous solutions. Pharm Res. 1996;13(9):1401–1405.8893282
   PubMed Web of Science ®Google Scholar
• Bonnet M, Hong CR, Gu YC, et al. Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers. Bioorg Med Chem. 2014;22(7):2123–2132. doi:10.1016/j.bmc.2014.02.03924650701
   PubMedGoogle Scholar
• Mallia MB, Mathur A, Sarma HD, Banerjee SA. (99m)Tc-labeled misonidazole analogue: step toward a (99m)Tc-alternative to [18F]fluromisonidazole for detecting tumor hypoxia. Cancer Biother Radiopharm. 2015;30(2):79–86. doi:10.1089/cbr.2014.170525569675
   PubMedGoogle Scholar
• Aguilera KY, Brekken RA. Hypoxia Studies with Pimonidazole in vivo. Bio-Protocol. 2014;4:19. doi:10.21769/BioProtoc.1254
   Google Scholar
• Zeng Y-C, Wu R, Xiao Y-P, et al. Radiation enhancing effects of sanazole and gemcitabine in hypoxic breast and cervical cancer cells in vitro. Contemp Oncol (Pozn). 2015;19(3):236–240. doi:10.5114/wo.2015.5182026557765
   PubMedGoogle Scholar
• Hassan Metwally MA, Jansen JA, Overgaard J. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial. Clin Oncol (R Coll Radiol). 2015;27(3):168–175. doi:10.1016/j.clon.2014.11.02425530485
   PubMedGoogle Scholar
• Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014;53(5):654–661. doi:10.3109/0284186X.2013.86405024328536
   PubMed Web of Science ®Google Scholar
• White CL, Menghistu T, Twigger KR, et al. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene Ther. 2008;15(6):424–433. doi:10.1038/sj.gt.330308118079753
   PubMedGoogle Scholar
• Winters T, Sercel A, Suto C, et al. Design and synthesis of 2-nitroimidazoles with variable alkylating and acylating functionality. Chem Pharm Bull. 2014;62(3):301–303.24583786
   PubMed Web of Science ®Google Scholar
• Hunter FW, Wouters BG, Wilson WR. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. Br J Cancer. 2016;114(10):1071–1077. doi:10.1038/bjc.2016.7927070712
   PubMedGoogle Scholar
• Baran N, Molecular Pathways: KM. Hypoxia-Activated Prodrugs in Cancer Therapy. Clin Cancer Res. 2017;23(10):2382–2390. doi:10.1158/1078-0432.CCR-16-089528137923
   PubMed Web of Science ®Google Scholar
• Takakusagi Y, Kishimoto S, Naz S, et al. Radiotherapy synergizes with the hypoxia-activated prodrug evofosfamide: in vitro and in vivo studies. Antioxid Redox Signal. 2018;28(2):131–140. doi:10.1089/ars.2017.710628741367
   PubMedGoogle Scholar
• Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007;13(13):3922–3932. doi:10.1158/1078-0432.CCR-07-047817606726
   PubMedGoogle Scholar
• Guise CP, Abbattista MR, Singleton RS, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 2010;70(4):1573–1584. doi:10.1158/0008-5472.CAN-09-323720145130
   PubMed Web of Science ®Google Scholar
• Kim EY, Liu Y, Akintujoye OM, et al. Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo. Radiat Res. 2012;178(3):126–137.22862779
   PubMed Web of Science ®Google Scholar
• Penketh PG, Shyam K, Zhu R, Baumann RP, Ishiguro K, Sartorelli AC. Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119W. Chem Res Toxicol. 2014;27(5):818–833. doi:10.1021/tx500004y24618018
   PubMedGoogle Scholar
• Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res. 2003;9(15):5714–5720.14654556
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-3-(2-nitro-1-imidazolyl)propylamino −7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res. 2000;12(4):185–192.11341468
   PubMed Web of Science ®Google Scholar
• Miller TJ, Schneider RJ, Miller JA, et al. Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3. Neurotoxicology. 2006;27(1):44–59. doi:10.1016/j.neuro.2005.06.00116125243
   PubMedGoogle Scholar
• Breider MA, Pilcher GD, Graziano MJ, Gough AW. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol. 1998;26(2):234–239. doi:10.1177/0192623398026002079547861
   PubMedGoogle Scholar
• Sharma R, Sharma A. 2-Nitroimidazole as Potential Nanoprobe in Hypoxia Imaging by MRI/PET. Boca Raton: Crc Press-Taylor & Francis Group; 2008.
   Google Scholar
• Parkinson EI, Bair JS, Cismesia M, Hergenrother PJ. Efficient NQO1 substrates are potent and selective anticancer agents. ACS Chem Biol. 2013;8(10):2173–2183. doi:10.1021/cb400583223937670
   PubMedGoogle Scholar
• Ger M, Kaupinis A, Nemeikaite-Ceniene A, et al. Quantitative proteomic analysis of anticancer drug RH1 resistance in liver carcinoma. Biochim Biophys Acta. 2016;1864(2):219–232. doi:10.1016/j.bbapap.2015.11.00526596252
   PubMedGoogle Scholar
• Celik A, Yetis G. An unusually cold active nitroreductase for prodrug activations. Bioorg Med Chem. 2012;20(11):3540–3550. doi:10.1016/j.bmc.2012.04.00422546205
   PubMedGoogle Scholar
• Jaberipour M, Vass SO, Guise CP, et al. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Biochem Pharmacol. 2010;79(2):102–111. doi:10.1016/j.bcp.2009.07.02519665450
   PubMedGoogle Scholar
• Amaia A, Pachon G, Cascante M, Creppy EE, Monge A. Lopez de Cerain A. Selective toxicity of a quinoxaline 1,4-di-N-oxide derivative in human tumour cell lines. Arzneimittel-Forschung. 2005;55(3):177–182.15819391
   PubMed Web of Science ®Google Scholar
• Gu Y, Jaiswal JK, Wang J, Hicks KO, Hay MP, Wilson WR. Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution. J Pharm Sci. 2014;103(11):3464–3472. doi:10.1002/jps.2409925212501
   PubMedGoogle Scholar
• Wang J, Guise CP, Dachs GU, et al. Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. Biochem Pharmacol. 2014;91(4):436–446. doi:10.1016/j.bcp.2014.08.00325130546
   PubMedGoogle Scholar
• Hunter FW, Wang J, Patel R, et al. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs. Biochem Pharmacol. 2012;83(5):574–585. doi:10.1016/j.bcp.2011.12.00522182429
   PubMedGoogle Scholar
• Wang J, Foehrenbacher A, Su J, et al. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res. 2012;18(6):1684–1695. doi:10.1158/1078-0432.CCR-11-229622167409
   PubMed Web of Science ®Google Scholar
• Hicks KO, Siim BG, Jaiswal JK, et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res. 2010;16(20):4946–4957. doi:10.1158/1078-0432.CCR-10-143920732963
   PubMed Web of Science ®Google Scholar
• Shen X, Laber CH, Sarkar U, et al. Exploiting the inherent photophysical properties of the major tirapazamine metabolite in the development of profluorescent substrates for enzymes that catalyze the bioreductive activation of hypoxia-selective anticancer Prodrugs. J Org Chem. 2018;83(6):3126–3131. doi:10.1021/acs.joc.7b0303529461834
   PubMedGoogle Scholar
• Manley E Jr., Waxman DJ. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. J Pharmacol Exp Ther. 2013;344(2):368–377. doi:10.1124/jpet.112.20008923192656
   PubMed Web of Science ®Google Scholar
• Nesbitt H, Byrne NM, Williams SN, et al. Targeting hypoxic prostate tumors using the novel hypoxia-activated prodrug OCT1002 inhibits expression of genes associated with malignant progression. Clin Cancer Res. 2017;23(7):1797–1808. doi:10.1158/1078-0432.CCR-16-136127697998
   PubMedGoogle Scholar
• Failes TW, Cullinane C, Diakos CI, Yamamoto N, Lyons JG, Hambley TW. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: A potential hypoxia-activated prodrug. Chem Eur J. 2007;13(10):2974–2982. doi:10.1002/chem.20060113717171733
   PubMedGoogle Scholar
• Schreiber-Brynzak E, Pichler V, Heffeter P, et al. Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. Metallomics. 2016;8(4):422–433. doi:10.1039/c5mt00312a26860208
   PubMed Web of Science ®Google Scholar
• Oszajca M, Collet G, Stochel G, Kieda C, Brindell M. Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues. Biometals. 2016;29(6):1035–1046. doi:10.1007/s10534-016-9974-927812766
   PubMedGoogle Scholar
• Xie D, Kim S, Kohli V, et al. Hypoxia-responsive (19)F MRI probes with improved redox properties and biocompatibility. Inorg Chem. 2017;56(11):6429–6437. doi:10.1021/acs.inorgchem.7b0050028537705
   PubMed Web of Science ®Google Scholar